Physician profile
Morgan Ryals
NPI 1295322311
$5,645.63
in general payments reported to CMS, 2019-2025
34 companies · $1,077 in 2025
The $1,077 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,097 · 2022: $1,445 · 2023: $1,176 · 2024: $851 · 2025: $1,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,077 · Gift: $27.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,076.82 |
| Gift | $27.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $694.43 | 2021-2023 | Tezspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $689.88 | 2023-2025 | Trulance, Xifaxan, Relistor |
| Abbvie INC. | $576.80 | 2021-2025 | |
| Glaxosmithkline, LLC. | $470.07 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $430.44 | 2021-2023 | Cyltezo |
| Ardelyx, INC. | $390.47 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $305.96 | 2022-2025 | |
| Janssen Biotech, INC. | $287.85 | 2023-2025 | Stelara, Tremfya |
| Regeneron Healthcare Solutions, INC. | $277.97 | 2021-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $201.62 | 2022-2025 | Gattex, Entyvio |
| Madrigal Pharmaceuticals | $177.92 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $137.09 | 2021-2024 | Dificid |
| Actelion Pharmaceuticals US, INC. | $120.48 | 2021-2022 | |
| Grifols USA, LLC | $101.30 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $97.03 | 2024 | Voquezna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $71.24 | 2024-2025 | Vowst |
| Mylan Specialty L.P. | $61.16 | 2022 | |
| Jazz Pharmaceuticals INC. | $58.87 | 2022 | |
| Braintree Laboratories, INC. | $58.09 | 2023-2024 | Suflave, Sutab |
| Nestle Healthcare Nutrition INC. | $46.33 | 2022-2023 | |
| Amgen INC. | $43.74 | 2022 | |
| Fisher & Paykel Healthcare INC | $43.24 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $43.09 | 2025 | Iqirvo |
| Insmed, INC. | $42.10 | 2021-2022 | |
| Pfizer INC. | $36.25 | 2024-2025 | |
| Advanced Respiratory, INC | $36.22 | 2021 | |
| Novo Nordisk INC | $35.11 | 2025 | Wegovy |
| Ethicon INC. | $24.79 | 2022 | |
| Tactile Systems Technology INC | $18.69 | 2022 | |
| Ironwood Pharmaceuticals, INC | $18.51 | 2024 | |
| Intercept Pharmaceuticals, INC. | $15.53 | 2023 | Ocaliva |
| Gilead Sciences, INC. | $14.94 | 2025 | |
| Lilly USA, LLC | $13.83 | 2025 | Omvoh |
| Inogen, INC. | $4.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Ryals listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.